Galapagos shares down after announcing clinical-trial miss for Crohn’s disease
U.S.-listed shares of Galapagos (GLPG) were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn’s disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. Galapagos plans to initiate a Phase 3 trial this year evaluating filgotinib as a treatment for AxSpA, a type of arthritis.